In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. More: Halozyme buys subcutaneous drug delivery peer Elektrofi for up to 0M Source: fierce
read moreIn the latest instance of pharma tariff whiplash, the import duties promised by the president last week are reportedly on hold. More: Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat Source: fierce
read moreThe FDA issued a complete response letter in response to Zydus’s bid to commercialize the first approved treatment for rare, often fatal pediatric disease Menkes disease. More: FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues Source:
read moreWith a government shutdown now in effect, the U.S. FDA—already shaken up by head count reductions earlier this year—has sought to keep many of its functions running for the foreseeable future. More: FDA avoids the worst amid government shutdown, but
read moreAbbVie has kicked off work on a $70 million expansion of its bioresearch center in Worcester, Massachusetts, where the company conducts both manufacturing and R&D for biologic medicines. The project falls under the banner of AbbVie’s broader U.S. investment announced
read more© 1994 - 2026 B.M. Pharmaceuticals